Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the women's environment, cancer and radiation epidemiology study
Antineoplastic Agents, Hormonal
Antineoplastic Combined Chemotherapy Protocols
Estrogen Receptor Modulators
Neoplasms, Second Primary
The associations between chemotherapy and tamoxifen treatment and reduced risk for contralateral breast cancer appear to continue for 10 and 5 years, respectively, after the initial breast cancer is diagnosed. Ovarian suppression may have a role in the association between chemotherapy and reduced risk for contralateral breast cancer.